OLBA HEALTHCARE HOLDINGS, INC.
2689・Standard Market・Wholesale Trade
Business
Orval Healthcare Holdings Co., Ltd. is a holding company for a medical equipment trading group founded in 1967. Its core Medical Equipment and Materials Business (approximately 93% of group sales) sells Surgery-related Consumables, Orthopedic Consumables, Cardiovascular Consumables, and Equipment and Fixtures to medical institutions. Through 9 consolidated subsidiaries, including Kawanishi Co., Ltd., Sansei Ikiki Co., Ltd., and Nikko Medical Instruments Co., Ltd., the group operates nationwide from its base in Okayama. The SPD Business provides materials and procurement management services for medical institutions, while the Nursing Care Products Business offers sales and rental of home nursing care beds and supplies. Major customers are medical and nursing care facilities such as hospitals and clinics, with MC Healthcare Co., Ltd. being the largest customer, accounting for 12.1% of net sales.
Business Model
The company is fundamentally a trading-company model that purchases products from medical device manufacturers and sells/supplies them to medical institutions. The core of revenue is consumables in the surgery-related, orthopedic, and cardiovascular fields (87.6% of Medical Equipment and Materials Business sales); once a facility is secured, ongoing consumables demand generates stable earnings. The SPD Business has multiple revenue sources, including outsourced materials management operations and management fee income, while the Nursing Care Products Business generates rental income. Negotiating the pass-through of rising procurement costs into selling prices is an important challenge for margin management.
Company Strengths
Consumables sales in the Medical Equipment and Materials Business expanded to ¥103,425 million (up 6.5% year on year) in FY2025 (ended June 2025). All three areas—surgery-related, orthopedic, and cardiovascular—grew in tandem, building a revenue structure less susceptible to fluctuations in demand for Equipment and Fixtures. The consumables ratio reached 87.6%.
Orthopedic Consumables grew 10.6% year on year (¥28,885 million), and Cardiovascular Consumables grew 7.2% year on year (¥24,083 million). Growth was driven by newly acquired facilities reaching full operation and proactive engagement with new technology areas such as robotic surgery and catheter ablation.
The simple average ROE over the past five years remained high at 14.2%. The equity ratio stood at 26.7% (up 0.4 points year on year), with net assets of ¥12,255 million. Operating cash flow secured was ¥1,626 million, and liquidity is managed under a policy of maintaining a month-end cash and deposit balance of approximately ¥2,000 million.
ENVALITH's Perspective
Performance Trend
Revenue over the past five fiscal years has been on a recovery trend following the FY2022 downturn, and is progressing largely in line with plan toward the full-year FY2026 (ending June 2026) forecast of ¥127,978 million (up 4.3% year on year), with cumulative 3Q revenue of ¥95,777 million (up 3.6% year on year). Operating profit, on the other hand, peaked at ¥2,227 million in FY2024 and has remained at low levels since, at ¥1,980 million in FY2025 and a full-year FY2026 forecast of ¥2,000 million. As an external factor, cost increases from the global rise in prices continue, and delays in passing these costs on to selling prices are squeezing gross profit. In addition, increased SG&A expenses from human capital investment and DX investment have compounded the pressure, keeping the cumulative 3Q operating margin at just 1.3%. Cumulative 3Q profit attributable to owners of parent was ¥872 million (down 6.5% year on year), with the decline widening.
Growth Strategy
Through four pillars—strengthening the core consumables business, OLBA-DX, overseas expansion, and development of new businesses—the company aims to achieve net sales of ¥142,000 million and operating profit of ¥2,700 million in FY2028 (ending June 2028).
The company continues to acquire facilities in high-growth areas such as orthopedics and cardiovascular, while persistently pursuing negotiations to pass through rising procurement costs to selling prices. Strengthening of the sales base, including the elevation of the Kansai branch, has driven cumulative 3Q consumables sales up 3.7% year on year, but delays in cost pass-through are squeezing margins, making improvement an urgent priority.
The company continues to invest in systems aimed at improving operational efficiency, inventory management, and reducing delivery costs. SPD Business sales are expanding steadily, up 6.7% year on year, driven by an increase in contracts for Medilia®, an original system for small and medium-sized medical institutions, but increased SG&A expenses from DX investment are pressuring profits in the short term.
With a long-term goal of “generating 20% of operating profit from overseas,” the company is advancing the establishment of a business foundation in the Kingdom of Thailand through THAI OLBA Healthcare Co.,Ltd. The current contribution to results is minor, as the business remains in the foundation-building stage.
Temasack®, an automated payment machine for clinics, continues to steadily expand its contracts. OLSTECH® (OLSTECH), a next-generation waste processing machine developed by Orseed Co., Ltd., established in January 2025, is advancing preparations for market rollout. Both currently have a limited contribution to results.
Last updated: July 17, 2026